HIV antibody safety study for newborns at risk
Treatments studied
Part of Infections clinical trials.
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The infant's birth parent has HIV infection and is willing to provide consent.
- The infant was born at 36 weeks or later, weighing at least 4.4 pounds (2 kg).
- The infant is less than 72 hours old at the start and will receive the study product within 72 hours of birth.
- The infant has normal blood counts (hemoglobin, platelets, white blood cells) and liver function.
- The infant is generally healthy and at higher risk of getting HIV (for example, if the birthing parent had high virus levels or wasn't on HIV medication).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
This study looks at whether two HIV medicines given as injections every 4 weeks—cabotegravir and rilpivirine—are safe and effective for pregnant women with HIV who have an undetectable viral load. The goal is to help pregnant people with HIV stay healthy and reduce the risk of passing HIV to their baby.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
This trial tests whether giving a special neutralizing antibody (bNAb) early to infants living with HIV can help their immune system fight the virus better. It's for babies under 1 year old who are starting HIV treatment for the first time.
This trial tests whether an experimental HIV vaccine, given with an adjuvant to boost the immune response, is safe and produces an immune response in infants who were exposed to HIV in the womb but are not infected. The study aims to help protect these vulnerable infants.
This trial tests whether giving early neutralizing antibodies can help infants living with HIV control the virus better. It aims to improve their long-term health.
Hear when a new HIV-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.